NAMS
NewAmsterdam Pharma Company N.V.
NASDAQ · NLHealthcareBiotechnology
$29.67-6.34%
Price as of Jul 20, 2026
NAMS financials
NewAmsterdam Pharma Company N.V. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Cost of revenue | $59.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $22.4M | $45.6M | $14.1M | $102.7M |
| Operating expenses | $248.1M | $221.9M | $197.1M | $106.3M |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M |
| EBITDA | -$242.3M | -$241.5M | -$176.9M | -$22.3M |
| Basic EPS | $-1.75 | $-2.56 | $-2.15 | $-1.19 |
| Diluted EPS | $-1.75 | $-2.56 | $-2.15 | $-1.19 |
| Balance sheet | ||||
| Cash & equivalents | $490.0M | $771.7M | $340.4M | $467.7M |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M |
| Stockholders’ equity | $683.4M | $757.5M | $288.4M | $430.1M |
| Total debt | $202.0K | $448.0K | $60.0K | $126.0K |
| Net debt | -$489.8M | -$771.3M | -$340.4M | -$467.6M |
| Cash flow | ||||
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M |
| Capital expenditure | -$246.0K | -$672.0K | -$24.0K | -$221.0K |
| Free cash flow | -$148.0M | -$159.2M | -$141.2M | $10.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |